 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Alnylam Reports Positive Phase I Data on ATTR Drug; Sees Pfizer Drug Setback as FDA Guide
July 19, 2012
Alnylam Reports Positive Phase I Data on ATTR Drug; Sees Pfizer Drug Setback as FDA Guide
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam Releases Positive Phase I Data on ATTR Drug; on Track to Move Newer Version into Clinic in '12
December 1, 2011 / Gene Silencing News - RNAi Drugs Field Sees Candidate Failures as More Drugs Enter the Clinic
November 17, 2011 / Gene Silencing News - Amid Advances in Lipid-Based Delivery, Some See Other Technologies Being Passed Over
January 13, 2011 / Gene Silencing News - Key RNAi-Based Drugs in the Clinic
November 12, 2009 / Gene Silencing News - For Some RNAi Rx Shops, Industry Deals with Bigger Players are Par for the Course
August 20, 2009 / Gene Silencing News